0
0
Published: July 30, 2026
An advisory committee to the U.S. Food and Drug Administration (FDA) voted 9–3 on July 29, 2026, against recommending Capricor Therapeutics’ experimental cell therapy, deramiocel, for the treatment of heart disease in patients with Duchenne muscular dystrophy (DMD). Meeting in Silver Spring, Maryland, the Cellular, Tissue, and Gene Therapies Advisory Committee concluded that the biotech firm failed to provide “substantial evidence” of the treatment’s clinical efficacy.
The nonbinding recommendation deals a significant blow to hopes for the first therapy explicitly targeted at Duchenne-related cardiomyopathy, the leading cause of death among young men with the disease. The FDA is scheduled to make its final regulatory decision by August 22, 2026. While the agency is not legally bound by advisory panel votes, it historically aligns with its independent experts.
Conflict Over Statistical Integrity in HOPE-3 Trial
At the center of the panel’s rejection was the Phase 3 HOPE-3 trial, a 12-month study involving 106 male participants aged 10 to 22 across 20 U.S. clinical sites. Participants were randomly assigned to receive quarterly intravenous infusions of either deramiocel or a placebo.
Capricor initially reported positive top-line results in late 2025, asserting that the trial successfully slowed the decline of upper-limb muscle function and preserved cardiac performance. However, FDA briefing documents revealed a deep rift between regulatory staff and the company regarding how the trial’s data was analyzed.
FDA reviewers testified that Capricor made multiple post-hoc modifications to its statistical analysis plan after trial completion—altering endpoints and analytical models without prior agency alignment. According to the FDA, analyzing the data under the original, pre-specified plan failed to demonstrate statistical significance. Capricor executives countered that the agency was judging the study based on an outdated, unapproved draft plan.
Adding further complexity, full results of the HOPE-3 trial were published in The Lancet on July 29, the exact day of the panel review. While the published data showed a statistically significant 54% slowing in the decline of upper-limb function ($p = 0.029$), the primary cardiac endpoint—changes in left ventricular ejection fraction (LVEF)—failed to achieve statistical significance across the full study population ($p = 0.0935$).
Expert Commentary: Unmet Need Meets High Evidentiary Bars
Panel members voiced deep empathy for families navigating Duchenne muscular dystrophy but stressed that regulatory standards could not be lowered despite the high unmet medical need.
“There is just not sufficient evidence for effectiveness, and it’s unfortunate that for such a huge clinical need that we are unable to provide something,” said Dr. Mladen Vidovich, an interventional cardiologist at UI Health in Chicago, during committee deliberations.
Other experts echoed concerns about the robustness of the clinical trial data.
“Believe me, I really, really want to see something work in this area. And there are some glimpses there. But I would not be able to at this time consider it strong support,” noted Dr. John Teerlink, a professor of clinical medicine at the University of California, San Francisco.
Dr. Steven Pavlakis of SUNY Downstate Health Sciences University summarized the panel’s consensus succinctly: “For both upper limb and heart outcomes, the data that we have is very fragile.”
Understanding Duchenne Cardiomyopathy and Deramiocel
Duchenne muscular dystrophy is a rare, severe X-linked genetic disorder occurring in approximately 1 in 3,500 to 5,000 male births. Mutations in the DMD gene prevent the body from producing dystrophin, a critical structural protein that protects muscle fibers from damage during contraction.
Over time, progressive muscle degeneration leads to loss of mobility, typically leaving patients wheelchair-dependent by their early teens. While modern respiratory care and corticosteroid regimens have substantially extended life expectancy into early adulthood, heart tissue weakness—known as dilated cardiomyopathy—causes progressive heart failure and remains the primary cause of mortality in older patients.
| Aspect | Current Standard Care | Deramiocel Approach |
| Primary Target | Skeletal muscle integrity, inflammation control | Cardiac and skeletal muscle fibrosis, inflammation |
| Mechanism | Steroids, gene transfer/exon skipping for dystrophin | Allogeneic cardiosphere-derived cells (cell therapy) |
| Heart Impact | Indirect management via blood pressure therapies | Direct immunomodulatory and anti-fibrotic repair |
Unlike corrective gene therapies that aim to restore micro-dystrophin, deramiocel uses donor-derived (allogeneic) cardiosphere-derived cells. The therapy functions as an immunomodulatory agent, secreting extracellular vesicles containing microRNAs that reduce tissue inflammation and prevent scar tissue formation (fibrosis) in both skeletal and cardiac muscle.
Broader Implications for Rare Disease Drug Development
The outcome highlights the persistent tension between regulatory flexibility in rare disease research and the requirement for definitive clinical proof. In rare conditions like DMD, small patient populations severely constrain sample sizes, making large-scale clinical trials challenging to conduct.
Capricor CEO Dr. Linda Marbán defended the company’s protocol adjustments, comparing the FDA’s evaluation to “a professor grading a term paper based on an early draft you never submitted.”
Conversely, regulatory scientists maintained that post-hoc alterations to trial protocol endpoints undermine scientific rigor and open trial results to bias. Analysts note that an explicit FDA rejection on August 22 could require Capricor to conduct an additional confirmatory trial before seeking approval again, potentially delaying access by years.
What Patients and Caregivers Should Know
For individuals living with DMD and their families, the advisory panel’s vote does not alter current treatment protocols. Because deramiocel remains an investigational product, healthcare providers emphasize that standard care management remains the primary defense against cardiac decline.
Medical specialists recommend that young men with Duchenne receive regular cardiac evaluations, including non-invasive imaging like echocardiograms and cardiac magnetic resonance imaging (MRI). Standard cardiac medications, such as ACE inhibitors, angiotensin receptor blockers, and mineralocorticoid receptor antagonists, remain the primary tools used by cardiologists to delay heart failure progression.
Patients and families interested in novel treatments are encouraged to consult their neuromuscular specialists about ongoing clinical trial opportunities and emerging therapeutic pipelines.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
